Safety and Efficacy of Medical Cannabis in Fibromyalgia Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra and Victor Novack Journal of Clinical Medicine, 2019, 8, 807 doi : 10.3390/jcm8060807 Abstract : Background : Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and eectiveness of medical cannabis therapy for fibromyalgia. Methods : A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017. Results : Among the [...]
Lire la suiteWhat Are the Benefits of CBD ? More than 60 percent of CBD users were taking it for anxiety, according to a survey of 5,000 people. Does it help? THE NEW YORK TIMES, By Dawn MacKeen Published Oct. 16, 2019 https://www.nytimes.com/2019/10/16/style/self-care/cbd-oil-benefits.html Credit...Photo Illustration by The New York Times; Shutterstock The CBD industry is flourishing, conservatively projected to hit $16 billion in the United States by 2025. Already, the plant extract is being added to cheeseburgers, toothpicks and breath sprays. More than 60 percent of CBD users have taken it for anxiety, according to a survey of 5,000 people, conducted by the Brightfield Group, a cannabis market [...]
Lire la suiteFDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease FDA is also working quickly to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD October 22, 2019 https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parkinson’s and Alzheimer’s disease, [...]
Lire la suiteResearch ethics aspects of experimentation with LSD on human subjects : a historical and ethical review Bodnár Kristóf János, Kakuk Péter Medicine, Health Care and Philosophy © Springer Nature B.V. 2018 https://doi.org/10.1007/s11019-018-9871-9 Abstract In this paper our aim is to examine whether research conducted on human participants with LSD-25 (lysergic acid diethylamide) raises unique research ethical questions or demands particular concerns with regard to the design, conduct and follow-up of these studies, and should this be the case, explore and describe those issues. Our analysis is based on reviewing publications up to date which examine the clinical, research and other uses of LSD and those addressing [...]
Lire la suiteSome distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity Rachael Ingram, Heather Kang, Stafford Lightman, David E. Jane, Zuner A. Bortolotto, Graham L. Collingridge, David Lodge, Arturas Volianskis Neuropharmacology, 2018, 142, 30e40 https://doi.org/10.1016/j.neuropharm.2018.06.008 Abstract Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, which may arise from a combination of several inter-related actions. Firstly, reductions of the contribution of NMDA receptors to afferent information from external and internal sensory inputs may distort sensations and their processing in higher brain centres. Secondly, reductions of NMDA receptormediated excitation of GABAergic interneurons can result in [...]
Lire la suiteCould cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013 Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]
Lire la suiteThe Varieties of Psychedelic Epistemology Chris Letheby Published in N. Wyrd, D. Luke, A. Tollan, C. Adams, and D. King (eds.) : "Psychedelicacies: more food for thought from Breaking Convention", Strange Attractor Press, 2019. INTRODUCTION Is it possible to gain knowledge1 by taking psychedelic2 drugs? One influential answer is ‘yes’: according to this conception, by inducing mystical states of consciousness, psychedelics afford direct knowledge of supernatural, transcendent dimensions of reality. This is an entheogenic conception of the drugs as agents that “generate the divine within”. A second influential answer is ‘no’: since materialism or physicalism3 is true, there are no transcendent realities, and psychedelics [...]
Lire la suiteMedicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review Mina Cheraghi Niroumand, Mohammad Hosein Farzaei, Gholamreza Amin Journal of Traditional Chinese Medicine, 2015, 35, (1), 104-109. Abstract OBJECTIVE : To review the pharmacological activities of Peganum harmala L. (P. harmala, Nitrariaceae) in traditional Iranian medicine (TIM) and modern phytotherapy. METHODS : Opinions of TIM and modern phytotherapy about safety and acceptable dosage of this plant are discussed. Various medical properties of P. harmala were collected from important TIM references and added to scientific reports derived from modern medical databases like PubMed, Scirus, ScienceDirect and Scopus. RESULTS : The main medicinal [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteTherapeutic potential of cannabinoid medicines Philip J. Robson Drug and Testing Analysis, 2014 Doi : 10.1002/dta.1529 Cannabis was extensively used as amedicine throughout the developed world in the nineteenth century but went into decline early in the twentieth century ahead of its emergence as the most widely used illicit recreational drug later that century. Recent advances in cannabinoid pharmacology alongside the discovery of the endocannabinoid system (ECS) have re-ignited interest in cannabis-based medicines. The ECS has emerged as an important physiological system and plausible target for new medicines. Its receptors and endogenous ligands play a vital modulatory role in diverse functions including immune response, [...]
Lire la suite